All In Biotech

Drug Trial Radar · NCT04072835

Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303

The NODE-303 Study: Multi-Centre, Multi-National,Open Label, Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia.

Last checked: Nov 20, 2026Latest source record: May 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,116

Actual

Start

Sep 23, 2019

Primary completion

Jan 26, 2023

Study completion Jan 26, 2023

Sponsor

Lead sponsor
Milestone Pharmaceuticals Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
IQVIA Biotech
First posted
Aug 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

NODE-303 was a multi-center, open label study to evaluate the safety of etripamil NS in participants with Paroxysmal Supraventricular Tachycardia (PSVT). Participants were provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS was self-applied by the participant, when they felt the onset of PSVT symptoms. Participants self-administered etripamil NS if vagal maneuver was ineffective. After an episode of PSVT where study drug was administered, the participant returned to the investigative site and had the option to continue in NODE-303 and manage up to three subsequent episodes of PSVT with etripamil NS for a maximum of four episodes.

Conditions

  • Paroxysmal Supraventricular Tachycardia

Interventions

  • Etripamil NSDrug

    Participants were provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS was self-applied by the participant, when PSVT symptoms begin. Participants self-administered etripamil NS if vagal maneuver was ineffective. After implementation of protocol amendment 2.1, participants had the option to administer a second dose of etripamil 70 mg 10 minutes after the first dose, if symptoms persisted. After an episode of PSVT where drug was administered, the participant returned to the investigative site for a study visit and was given the option to continue in NODE-303 and manage up to three subsequent episodes of PSVT with etripamil NS for a maximum of four episodes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events for Self-administered Etripamil NS Outside of the Clinical Setting.Time frame: From Baseline until a maximum of 4 episodes of perceived PSVT are treated with study drug, up to a maximum duration of 40 months.

Locations

124 sites in 5 countries. Site status is shown where the registry gives one.

  • 1077

    Gilbert, Arizona

  • 1121

    Fremont, California

  • 1035

    Stanford, California

  • 1023

    Vista, California

  • 1083

    West Hills, California

  • 101

    Littleton, Colorado

  • 1010

    Bridgeport, Connecticut

  • 1066

    Trumbull, Connecticut

  • 1042

    Bradenton, Florida

  • 1106

    Daytona Beach, Florida

  • 1107

    Edgewater, Florida

  • 1032

    Hialeah, Florida

  • 1026

    Miami, Florida

  • 1055

    Miami, Florida

  • 1064

    Naples, Florida

  • 1071

    North Miami Beach, Florida

  • 1009

    Orlando, Florida

  • 1060

    Saint Augustine, Florida

  • 1022

    Cumming, Georgia

  • 137

    Macon, Georgia

  • 1115

    Coeur d'Alene, Idaho

  • 1045

    Peoria, Illinois

  • 149

    Fort Wayne, Indiana

  • 1025

    West Des Moines, Iowa

  • 1008

    Monroe, Louisiana

  • 1007

    Salisbury, Maryland

  • 1078

    Boston, Massachusetts

  • 166

    Lansing, Michigan

  • 119

    Rochester, Minnesota

  • 1093

    Saint Paul, Minnesota

  • 1099

    Kansas City, Missouri

  • 1134

    Elmer, New Jersey

  • 1133

    Haddon Heights, New Jersey

  • 114

    New York, New York

  • 1021

    Southampton, New York

  • 129

    Charlotte, North Carolina

  • 1065

    Charlotte, North Carolina

  • 1079

    Mount Airy, North Carolina

  • 1018

    Statesville, North Carolina

  • 1024

    Canton, Ohio

Showing 40 of 124 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.